CROI 2015 Program and Abstracts

Poster Listings

406 Multi-Dose Romidepsin in SIV-Infected RMs Reactivates Latent Virus in Absence of ART Benjamin Policicchio 1 ; Egidio Brocca-Cofano 1 ; Cuiling Xu 1 ; Dongzhu Ma 1 ; Hui Li 2 ; George Richter-Haret 1 ;Tammy Dunsmore 1 ; George M. Shaw 2 ; Ivona Pandrea 1 ; Cristian Apetrei 1 1 University of Pittsburgh, Pittsburgh, PA, US; 2 University of Pennsylvania, Philadelphia, PA, US 407 Suberanilohydroxamic Acid (SAHA)-Induced Histone Modifications in the HIV Promoter in a Human, Primary CD4 T Cell Model of Latency Brian Reardon 1 ; Amey Mukim 2 ; Savitha Deshmukh 2 ; Christopher H.Woelk 3 ; Douglas D. Richman 1 ; Celsa A. Spina 1 1 University of California San Diego, La Jolla, CA, US; 2 VA San Diego Healthcare System, La Jolla, CA, US; 3 University of Southampton, Southampton, United Kingdom 408 Donor-to-Donor Variation in the Host Gene Expression Response to SAHA Bastiaan Moesker 1 ; Brian Reardon 2 ; Nadejda Beliakova-Bethell 2 ; Akul Singhania 1 ; Michael S. Breen 1 ; Christopher H.Woelk 1 1 University of Southampton, Southampton, United Kingdom; 2 University of California San Diego, La Jolla, CA, US 409 Off-Target Effects of SAHA May Inhibit HIV Activation Cory H. White 1 ; Harvey E. Johnston 2 ; Antigoni Manousopoulou 2 ; Celsa A. Spina 1 ; Douglas D. Richman 1 ; Spiros D. Garbis 2 ; Christopher H.Woelk 2 ; Nadejda Beliakova-Bethell 1 1 University of California San Diego, La Jolla, CA, US; 2 University of Southampton, Southampton, United Kingdom 410 Bystander Effect of Histone Deacetylase Inhibitors on HIV-1 Infection Grant R. Campbell ; Rachel S. Bruckman;Yen-Lin Chu; Stephen A. Spector University of California San Diego, La Jolla, CA, US 411 HIV-1 Reactivation Increases Mitochondrial Priming of the Latent Reservoir Jeremy A. Ryan 2 ; Allison L. Schure 1 ; Zelda Euler 3 ; Anthony Letai 2 ; Athe Tsibris 1 1 Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, US; 2 Dana-Farber Cancer Institute, Boston, MA, US; 3 Ragon Institute of MIT, MGH and Harvard, Cambridge, MA, US 2:30 pm– 4:00 pm Pharmacologic Latency-Reactivation Agents 412 Reactivation of HIV Latently Infected T Cells by Targeting Tat IRES Translation Georges Khoury 1 ; Sri Ramarathinam 2 ; Charlene Mackenzie 1 ; DavidYurick 1 ; Con Sonza 1 ; Tony Purcell 2 ; Damian F. Purcell 1 1 University of Melbourne At the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia; 2 Monash University/Alfred Hospital, Melbourne, Australia 413 Targeting HIV-1 Latency With a Potent Tat Inhibitor Guillaume Mousseau 1 ; Remi Fromentin 2 ; Cari Kessing 2 ; LydieTrautmann 2 ; Nicolas Chomont 2 ; Susana T. Valente 1 1 The Scripps Reasearch institute, Jupiter, FL, US; 2 The Vaccine and Gene Therapy Institute, Port Saint Lucie, FL, US 414 Impact of IFN α -2a on the Replication-Competent HIV-1 Reservoir in CD4+ T Cells Sara Morón-López 2 ; Maria Salgado 2 ; Dan Ouchi 2 ; Mari Carmen Puertas 2 ;Toni Jou 3 ; Cristina Tural 3 ; Jordi Navarro 1 ; Mercedes Perez-Bernal 1 ; Manel Crespo 1 ; Javier Martínez-Picado 2 1 Hospital Universitari Vall d’Hebron, Barcelona, Spain; 2 AIDS Research Institute irsiCaixa, Barcelona, Spain; 3 Fundació Lluita contra la SIDA, Barcelona, Spain 415 Immune ModulationWith Rapamycin as a Potential Strategy for HIV-1 Eradication Alyssa R. Martin ; Robert F. Siliciano Johns Hopkins University School of Medicine, Baltimore, MD, US 416 Latency Reversing Agents Activate Latent Reservoirs in the Brain of SIV- Infected Macaques Lucio Gama 1 ; Sarah Price 1 ; Erin Shirk 1 ; Suzanne E. Queen 1 ; Ming Li 1 ; Brandon Bullock 1 ; StephenWietgrefe 2 ; Luiz Pianowski 3 ; M. Christine Zink 1 ; Janice Clements 1 1 Johns Hopkins University School of Medicine, Baltimore, MD, US; 2 University of Minnesota, Minneapolis, MN, US; 3 Bioqual, Valinhos, Brazil Session P-F7 Poster Session Poster Hall

417 TLR7 Agonist GS-9620 Activates HIV-1 in PBMCs FromHIV-Infected Patients on cART Derek D. Sloan 1 ; Alivelu Irrinki 1 ; AngelaTsai 1 ; Jasmine Kaur 1 ; Jay Lalezari 2 ; Jeff Murry 1 ; Tomas Cihlar 1 1 Gilead Sciences, Inc., Foster City, CA, US; 2 Quest Clinical Research, San Francisco, CA, US 418 Baracitinib, Ruxolitinib, Dasatinib Block HIV Replication, Activation, Reactivation Christina Gavegnano Emory University, Atlanta, GA, US 419 Ex Vivo Identification of Highly Effective Latency-Reversing Drug Combinations Gregory M. Laird 1 ; C Korin Bullen 1 ; Daniel I. Rosenbloom 2 ; Alyssa R. Martin 1 ; Alison L. Hill 3 ; Christine M. Durand 1 ; Janet D. Siliciano 1 ; Robert F. Siliciano 1 1 Johns Hopkins University School of Medicine, Baltimore, MD, US; 2 Columbia University, New York, NY, US; 3 Harvard University, Boston, MA, US 2:30 pm– 4:00 pm Latency Models and Assays 420 Investigating Mechanisms of HIV Persistence Using Droplet Digital PCR Approaches Elizabeth M. Anderson 1 ; Robert Gorelick 2 ; Shawn Hill 1 ; Catherine A. Rhem 5 ; Mary Kearney 1 ; JohnW. Mellors 3 ; John M. Coffin 4 ; Mike Piatak 2 ; Frank Maldarelli 1 1 National Cancer Institute at Frederick, Frederick, MD, US; 2 Leidos Biomedical Research, Inc, Frederick, MD, US; 3 University of Pittsburgh, Pittsburgh, PA, US; 4 Tufts University, Boston, MA, US; 5 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US 421LB High-Throughput Single-Cell Quantification of HDACi-Based HIV Reservoir Reactivation Robert W. Yucha 1 ; Emily Hanhauser 2 ; Kristen S. Hobbs 2 ; Helen Bae 3 ; Fatih Inci 4 ; Hadi Shafiee 2 ; ShuqiWang 4 ; Daniel Kuritzkes 1 ; Utkan Demirci 4 ;Timothy J. Henrich 1 1 Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA, US; 2 Brigham and Women’s Hospital, Cambridge, MA, US; 3 Harvard University, Cambridge, MA, US; 4 Stanford University, Palo Alto, CA, US 422 Evaluation of HIV-1 Latency-Reversing Agents by a Modified Virus Growth Assay (VOA) Riddhima Banga; Francesco Procopio; Matthias Cavassini; Alessandra Noto; Song Ding; Giuseppe Pantaleo; Matthieu Perreau Lausanne University Hospital, Epalinges, Switzerland 423 “Kick and Kill”of Latent HIV-1 Infection in Naïve and Central Memory CD4 + T cells Solutions Pawel Bonczkowski 2 ; Laura J. Martins 1 ;Ward de Spiegelaere 2 ; Alberto Bosque 1 ; Eva Malatinkova 2 ; Christopher H.Woelk 3 ; Cory H.White 4 ; AdamM. Spivak 5 ;Vicente Planelles 1 ; LinosVandekerckhove 2 1 University Of Utah School of Medicine, Salt Lake City, UT, US; 2 Ghent University and University Hospital, Ghent, Belgium; 3 University of Southampton, Southampton, United Kingdom; 4 University of California San Diego (UCSD), La Jolla, CA, US; 5 Utah University Hospital, Salt Lake City, UT, US 425 CD4+ Tissue-Resident Memory T Cells Are an Important Reservoir for HIV Persistence Angela R. Wahl ; J.Victor Garcia University of North Carolina, Chapel Hill, NC, US WEDNESDAY, FEBRUARY 25, 2015 Session P-F8 Poster Session Poster Hall Jennifer M. Zerbato ; Nicolas Sluis-Cremer University of Pittsburgh, Pittsburgh, PA, US 424 HIV Recombination in the In Vitro T CM Latency Model – Reasons and

Poster Listings

37

CROI 2015